Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „week“
Suchtreffer
Begriffe & Kennungen
Darunavir Viatris (previously Darunavir Mylan) · 4.8 · The safety assessment in paediatric patients is based on the 48-week analysis of safety data from three Phase
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.8 · The safety assessment of darunavir with ritonavir in paediatric patients is based on the 48-week analysis of s
Eintrag öffnenDescovy · 4.8 · The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in a single arm, open-lab
Eintrag öffnenDescovy · 4.8 · The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in a single arm, open-lab
Eintrag öffnenDescovy · 4.8 · The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an open- label clinica
Eintrag öffnenDescovy · 4.8 · The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an open- label clinica
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.8 · Most of these adverse reactions were grade 1 and occurred after 8 weeks.
Eintrag öffnenDuloxetine Lilly · 4.8 · In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain,
Eintrag öffnenDuloxetine Viatris (previously Duloxetine Mylan) · 4.8 · In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain,
Eintrag öffnenDuloxetine Zentiva · 4.8 · In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain,
Eintrag öffnenDupixent · 4.8 · 15 Asthma The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent wit
Eintrag öffnenDupixent · 4.8 · 77 The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent with the s
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenDupixent · 4.8 · Infections In the 16-week atopic dermatitis monotherapy clinical adult studies, serious infections were report
Eintrag öffnenDupixent · 4.8 · Infections In the 16-week atopic dermatitis monotherapy clinical adult studies, serious infections were report
Eintrag öffnen